Evidence map›Paper›PMID 38520613›Full record

Trial reportIrish journal of medical science2024

Validity of galactin-3 in acromegaly: comparison with traditional markers.

Maryam Thaer Saadi, Noor Ulhuda G Mohammed, Baydaa Ahmed Abed, Layla Othman Farhan, Isam Noori Salman

Abstract readComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Irish journal of medical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Maryam Thaer SaadiDepartment of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq.
Noor Ulhuda G MohammedDepartment of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq. noorulhuda.g@csw.uobaghdad.edu.iq.ORCID http://orcid.org/0000-0003-3549-1578
Baydaa Ahmed AbedNational Diabetes Center, Mustansiriyah University, Baghdad, Iraq.
Layla Othman FarhanDepartment of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq.
Isam Noori SalmanNational Diabetes Center, Mustansiriyah University, Baghdad, Iraq.
University of Baghdad · IQMustansiriyah University · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcromegaly occurs due to overproduction of growth hormone (GH) and insulin-like growth factor-1 (IGF-1). Galectin-3 (Gal-3) has recently emerged as a novel biomarker, related to IGF-1. This study aimed to assess Gal-3 in patients with acromegaly and compare its effectiveness with traditional biomarker tests. MATERIALS AND

methodsA randomized case control study conducted in a single center included 50 acromegaly patients and 40 apparently healthy subjects (HS) serve as control group matched both age and BMI. Laboratory test was measured by routine assay used in center. Gal-3, GH, and IGF-1 were measured by enzyme-linked immunosorbent assay (ELISA).

resultThere were 50 patients with an average age of 50.40 ± 12.229 (50% of males). Compared with HS, patients' serum GAL-3 levels have increased significantly. The serum GAL-3 exceeds 14.363 ng/ml, with a sensitivity of 100.0 and a specificity of 100.0. Furthermore, serum Gal-3 levels in combination with traditional tests (GH and IGF-1) by DeLoongs test had a significant difference in discriminating acromegaly more accurately than traditional tests.

conclusionIn a summary, this study recommended clinicians measure serum Gal-3 as biomarkers for patients with acromegaly. In addition, the result above shed light on role of Gal-3 on acromegaly pathogenesis and might provide a therapeutic target of acromegaly patients.

Indexed as

AcromegalyBiomarkersGalectin 3Insulin-Like Growth Factor IAdultBlood ProteinsCase-Control StudiesEnzyme-Linked Immunosorbent AssayFemaleGalectinsHuman Growth HormoneHumansMaleMiddle AgedBiomarkersBlood ProteinsGalectin 3GalectinsHuman Growth HormoneIGF1 protein, humanInsulin-Like Growth Factor ILGALS3 protein, humanAcromegalyCardiovascularGalectin-3Growth hormoneIGF-1Pituitary adenoma

Identifiers

PMID38520613
OpenAlexW4393113538

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.